Q3 2022
Released Nov 14, 2022, after the close
10-Q filed Nov 14, 2022, 45 days after period end · 0001628280-22-029889
Q3 2022 · 10-Q
Revenue—
Net Income-$29.35M-$29.35M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$1.61-$1.61 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$31,655,000N/M
Operating Cash Flowderived-$30,098,000—
Free Cash Flowderived-$34,889,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2022 | Q3 2021 |
|---|---|---|
| Net Income | -$29.35M | -$16.41M |
| EPS Diluted | -$1.61 | -$1.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR